Giparmen

Giparmen

SCHEMBL2109323

C#CCOc1ccc2c(C)cc(=O)oc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 1.00
KDM4E B2RXH2 5/20 1.00
GLA P06280 3/20 1.00
GAA P10253 3/20 1.00
TSHR P16473 1/20 1.00
HPGD P15428 4/20 0.76
HSD17B10 Q99714 4/20 0.76
ALDH2 P05091 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
L3MBTL1 Q9Y468 1/20 0.76
MAOA P21397 4/20 0.74
MAOB P27338 4/20 0.74
RAB9A P51151 3/20 0.62
NPC1 O15118 2/20 0.62
CASP3 P42574 2/20 0.62
SENP8 Q96LD8 2/20 0.62
SENP7 Q9BQF6 2/20 0.62
SENP6 Q9GZR1 2/20 0.62
TDP1 Q9NUW8 1/20 0.62
CA12 O43570 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66273 0.82 ALDH1A1 (0.78) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL29557901 0.82 ALDH1A1 (0.78) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL26195631 0.82 KDM4E (0.69) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL28463972 0.82 KDM4E (0.69) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL11502207 0.81 ALDH1A1 (0.67) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL11502202 0.80 KDM4E (0.67) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL11502116 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL9464272 0.80 MAOB (0.70) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL10063475 0.80 MAOB (0.74) ALDH1A1KDM4EGLAGAATSHR
SCHEMBL20832199 0.80 ALDH1A1 (0.65) ALDH1A1KDM4EGLAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-4151291-A ANALGESICS UNICLER (FR) 1979-04-24 US claimed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
CN-109678848-B Coumarin/pyridone hybrid derivative and preparation method and application thereof 浙江工业大学 2020-10-09 CN disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
WO-2018127654-A1 FUNCTIONALISED CELLULOSE MATERIAL UNIVERSITE DE NANTES (FR) 2018-07-12 WO disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140219925-A1 POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2014-08-07 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
EP-0370153-A1 Improvement process for debrominative rearrangements MERRELL DOW PHARMACEUTICALS INC. (US) 1990-05-30 EP disclosed
US-4151291-A ANALGESICS UNICLER (FR) 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140219925-A1 POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT ABCB1, TSG101, CD44 ALDH1A1 2840/4885KDM4E 4784/4885GLA 946/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 ALDH1A1 4459/4885KDM4E 4426/4885GLA 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.